Background Systematic explorations of language abilities in patients with amyotrophic lateral sclerosis (ALS) are lacking in the context of wider cognitive change.
Methodology Neuropsychological assessment data were obtained from 51 patients with ALS and 35 healthy controls matched for age, gender and IQ. Composite scores were derived for the domains of language and executive functioning. Domain impairment was defined as a composite score ≤5th centile relative to the control mean. Cognitive impairment was also classified using recently published consensus criteria.
Results The patients with ALS were impaired on language and executive composite scores. Language domain impairment was found in 43% of patients with ALS, and executive domain impairment in 31%. Standardised language and executive composite scores correlated in the ALS group (r=0.68, p<0.001). Multiple regression analyses indicated that scores on the executive composite accounted for 44% of the variance in language composite scores.
Conclusions Language impairments are at least as prevalent as executive dysfunction in ALS. While the two domains are strongly associated, executive dysfunction does not fully account for the profile of language impairments observed, further highlighting the heterogeneity of cognitive impairment in non-demented patients with ALS.
- Motor Neuron Disease
- Cognitive Neuropsychology
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
The clinical presentation of amyotrophic lateral sclerosis (ALS) extends beyond the motor system, and studies have reported cognitive impairments of varying severity. While a minority of patients meet criteria for the frontotemporal dementia (FTD) and/or primary progressive aphasia (PPA) subtypes of frontotemporal lobar degeneration (FTLD),1 approximately one-third show cognitive impairments of a milder nature.2–4 Executive dysfunction, a negative prognostic indicator of survival in ALS,5 has been the most commonly investigated cognitive domain in non-demented patients with ALS. Studies have often reported impairments in fluency, set-shifting, attention and inhibition.6–8 Recent consensus criteria have defined cognitive impairment in ALS on the basis of impaired scores (≤5th centile of age- and education-matched controls) on at least two measures of executive functioning.3 Cognitive impairments in ALS are not, however, restricted to the executive domain.4 A number of studies have reported impairments on tasks of language function including confrontation naming, single word and syntactic comprehension, and verb processing.4 ,9 ,10 It remains unclear whether this reflects an aphasia-like impairment11 or is secondary to executive dysfunction.12 There have been comparatively few investigations of language in non-demented patients with ALS and consequently the nature and frequency of language impairment occurrence has not been fully characterised. This study aimed to investigate the prevalence and profile of language change in ALS and the relationship with executive function.
Materials and methods
Patients were recruited primarily from The King's Motor Neurone Disease (MND) Care and Research Centre, London, UK. Additional patients were recruited from MND Care and Research Centres in Cambridge, Newcastle and Manchester, UK. Healthy control participants were recruited through a volunteer database (http://mindsearch.iop.kcl.ac.uk/). Ethics approval was obtained from King's College Hospital Research Ethics Committee (07/H0808/156). Appropriate institutional approvals were obtained to permit recruitment from additional centres. Informed written consent was obtained from all participants, consistent with the Declaration of Helsinki.
Exclusion criteria for all participants were not having English as a first language, cerebrovascular disease, hypertension, diabetes, history of head injury and current prescription of psychoactive medication. We included right-handed patients, aged <75 years with evidence of probable or definite ALS.13 Additional patient exclusion criteria included respiratory weakness (forced vital capacity < 70%), familial history of ALS, and a clinical diagnosis of comorbid dementia. Where recruited patients showed clinically evident behavioural and/or cognitive impairment at the initial interview, FTLD diagnostic criteria14 were applied to identify patients with FTD, PPA (either progressive non-fluent aphasia or semantic dementia). Patients meeting criteria were excluded.
Domains of language and executive functioning were assessed (table 1) as part of a broader battery of tests including memory function (see online supplementary material). Current and premorbid IQ were assessed using the Wechsler Abbreviated Scale of Intelligence15 and Wechsler Test of Adult Reading (WTAR),16 respectively. The Hospital Anxiety and Depression Scale (HADS)17 measured symptoms of anxiety and depression. In the patients, functional abilities were assessed using the Amyotrophic Sclerosis Functional Rating Scale Revised (ALSFRS-R).18 Patients were assessed in their homes, and control participants at the Institute of Psychiatry. Assessments were conducted over two sessions, approximately 1 week apart. A fixed test order was used to attempt to control for effects of fatigue and between-test interference across the two groups.
To avoid undertaking multiple between-group comparisons using individual tests, composite scores were calculated from selected indices for the language and executive domains (table 1). As successful completion of the assessment measures may depend on a combination of executive and linguistic abilities (eg, Hayling Sentence Completion Test, phonemic and semantic verbal fluency), total domain score–individual test score correlations were examined to determine the allocation of measures to cognitive composite scores. Standardised z scores for each test were calculated by subtracting the mean score of controls from the participant's score and then dividing the difference by the control group SD. All measures were adjusted such that a negative score indicated worse performance. z Scores in each domain were summed, and divided by the number of tests completed to give the composite score. Impairment was defined as a composite score ≤5th centile (∼1.64 SDs) below the control mean. Raw scores were used for secondary analyses to consider the variation in impairment across individual measures. As an alternative indicator of overall impairment, the consensus criteria requiring impairment on two or more tests of executive function were also applied, and extended to include classification of language impairment following impairment evident on two or more tests of language functioning.
The data were analysed using SPSS V.17. Demographic, clinical and cognitive characteristics were reported as percentages for categorical data and means for continuous variables. Between-group comparisons were undertaken using t tests or multivariate analysis of covariance. Categorical data were analysed using χ2 tests. Pearson's correlations and multiple regression analyses were used to examine the relationships between executive and language composite scores. Any outliers were identified and transformed to reduce their impact on the analysis. All tests were two-tailed, and statistical significance was set at p<0.05.
Demographic and clinical characteristics
Fifty-one patients with ALS and 35 healthy controls participated in the study. There were no significant differences between the groups with respect to gender distribution, age and years of education, current IQ or estimated premorbid IQ (table 2). Six patients with ALS were unable to complete the WTAR because of dysarthria, so premorbid IQ estimates were obtained for 45 patients with ALS. Patients had higher mean anxiety, depression and total HADS scores than controls, and the HADS total score was used as a covariate for subsequent between-group analyses. However, although participants’ HADS scores were not modified to account for physical impairment,32 the scores did not indicate clinically relevant levels of depression or anxiety.
The mean ALSFRS-R score at the time of neuropsychological assessment was 33.15 (SD 9.07). Seventy-five per cent of patients had limb-onset and 25% bulbar-onset disease, consistent with typical phenotype frequencies. The average time since onset of symptoms was less than 3 years, with an average delay from symptom onset to diagnosis of ∼12 months. Seventy per cent of patients with ALS were taking riluzole at the time of assessment.
Profile and prevalence of executive and language impairment
Multivariate analysis of covariance, with HADS total score entered as a covariate, revealed that the patient mean scores were significantly lower overall (more impaired) (F(4,79)=4.47, p<0.05). Univariate contrasts revealed that the mean patient scores were significantly lower for the executive domain (−0.42, SD=0.70 compared with 0.0, SD=0.37 for controls; F(1,83)=5.67, p=0.02, partial eta2=0.064) and for the language domain (−0.98, SD=1.31 compared with 0.0, SD=0.53 for controls; F(1,83)=8.42, p=0.005, partial eta2=0.092).
Based on the 5% cut-off derived from the control sample, 31% of the patients with ALS were classified as impaired on the executive composite and 43% on the language composite. Of the 23 patients with impairment on the language composite, 10 (43.5%) had executive composite scores within the normal range. Pearson's χ2 analysis revealed no relationship between bulbar-onset disease and impairment in the language (χ2(1)=0.81, p=0.37) and executive domains (χ2(1)=0.003, p=0.96).
Analysis of variance revealed no significant differences in age (F(3,51)=0.462, p=0.710, partial eta2=0.029), HADS scores (F(3,51)=1.223, p=0.312, partial eta2=0.072), years of education (F(3,51)=5.67, p=0.080, partial eta2=0.082), months since onset of illness (F(3,51)=0.930, p=0.434, partial eta2=0.056) and ALSFRS-R scores (F(3,51)=1.70, p=0.180, partial eta2=0.098) between the different cognitive profile groups (no impairment on executive or language composites, impairments on executive and language composites, impairments on the executive composite only, impairment on the language composite only).
Applying the consensus criteria3 of impairment on two or more tests of executive function, 13 (25%) patients were classified as cognitively impaired. Applying and extending the criteria to the language tests, 20 (39%) were impaired. Of these, seven (35%) performed within the normal range on all measures of executive functioning. Table 3 shows the raw scores on individual language and executive function tests and the proportion of patients meeting criteria for impairment (NB higher scores indicating worse performance). Executive function tests were differentially sensitive to impairment (6–26.5% of the patients were found to be impaired on individual measures) as were the language tests, with impairment noted in 4–49%, depending on the measure.
Relationship between executive and language domains within the ALS group
To normalise the distributions and equalise variance for within-group analysis, composite scores were restandardised for the ALS participants using the group means and SDs. Pearson's correlations examining associations between composite scores in the ALS group revealed a relationship between the severity of impairment measured by the executive and language (r=0.68, p<0.001) composites. A linear regression analysis indicated that the executive composite scores accounted for 44% of the variance in the language composite scores (standardised β=0.63, 95% CI 0.46 to 0.96, t(51)=5.80, p<0.001).
The findings of this study are broadly consistent with the extensive literature indicating executive dysfunction in approximately one-third of non-demented patients with ALS.2–4 Based on a composite measure of executive function, we found 31% of patients in the present sample to be impaired. This study has also highlighted the occurrence of mild language impairments in non-demented patients with ALS and suggests that such deficits may be at least as common as executive dysfunction, with 43% of patients showing impairment on the composite measure. A similar pattern was observed when extended consensus criteria were used, with impairment of 25% and 39% in executive and language domains, respectively.
The significant association between the severity of language and executive dysfunction and the common co-occurrence of impairment in the two domains is consistent with previous research that has interpreted impaired language abilities in non-demented patients with ALS as being a consequence of executive dysfunction rather than of a primary linguistic disorder.7 ,12 Although the precise mechanism by which executive dysfunction affected language is unclear, aspects of linguistic processing have been related to frontal pathology in ALS.33 Conversely, impairments in the executive domain noted may partly reflect language dysfunction and be interpreted as a consequence of impaired linguistic functions. While recognising the co-occurrence and association between impairment in the two cognitive domains, the results of this study suggest that the two deficits are, in part, dissociable. The two domains shared only 44% of variance in terms of performance, and over 40% of patients impaired on the language composite performed with the normal range on the executive composite, with a similar figure (35%) when impairment was based on the consensus criteria.
The present findings suggest that cognitive impairment in ALS is heterogeneous, with some patients showing a predominantly dysexecutive profile, others showing a predominantly linguistic profile, and some a mixed pattern. This is similar to the concept of single-domain and multiple-domain mild cognitive impairment seen in the prodromal stages of Alzheimer's disease and other dementias.34 It is also consistent with investigations of FTLD in patients with ALS that have highlighted both overlap and independence of FTD and PPA subtypes.35
The increasing awareness of mild cognitive change in non-demented patients with ALS has led to the development of brief screening tools36–38 and the publication of consensus criteria for optimal assessment of cognitive change.3 These criteria recommend that non-demented patients with ALS be considered as cognitively impaired following performance on standard neuropsychological testing ≤5th centile, compared with age- and education-matched norms, on two or more distinct cognitive tests sensitive to executive functioning. The significance of language impairment, either combined with executive impairment or in isolation, suggests that published screening tools and consensus criteria for diagnosing mild cognitive impairment may insufficiently address the heterogeneity of cognitive change in non-demented patients with ALS. Failure to include language dysfunction in the definition of cognitive change may therefore lead to underestimations of the prevalence rates of cognitive impairment.
In addition to implications for the formal assessment of cognitive change in ALS clinics, the findings are important when the more general awareness and understanding of cognition in ALS are considered. Increasing awareness of cognitive change is of importance to people with ALS and in the care of individuals with ALS, potentially reducing carer and patient anxiety about the presence of notable cognitive deficits. This study suggests that the observed heterogeneity in cognitive change seen in ALS needs to be further accepted in clinical practice to facilitate a model of effective management of patients with ALS that includes consideration of language impairments as well as executive dysfunction.
The findings of this study may inform future neuroimaging and pathological investigations. The observed heterogeneity of cognitive presentation may reflect variable involvement of frontal and temporal structures subserving executive and language functioning. Furthermore, and in consideration of neuroimaging investigations that have noted white matter tract abnormalities in frontotemporal white matter association tracts,33 it is also feasible that the cognitive presentation in ALS may be determined by differential degeneration of white matter. Future research combining in vivo neuropsychological assessment, neuroimaging and postmortem pathological investigation is required to determine the pathological processes and neuroanatomical changes in non-demented patients with ALS with varying cognitive presentations. Previous research has highlighted the role of genetic factors in determining the cognitive profile of patients with ALS with mild cognitive change.8 Given the present study's identification of differing presentations of cognitive change, future research could investigate the role of genetic risk factors, as has been undertaken in studies of FTLD.
This study has several limitations that may affect the interpretation of the results and generalisations to the wider ALS population, including use of prevalence rather than incidence sampling, and recruiting from specialist centres rather than community settings. This is a limitation of the majority of neuropsychological investigations of ALS, although some population-based studies have also confirmed the heterogeneity of cognitive impairment in ALS.4 While our exclusion criteria were important in ensuring that cognitive impairment could not be better explained by comorbid conditions and disease-related factors, the application of such criteria may render the present sample less representative of the ALS population as a whole, but more informative with respect to the effects of ALS on cognition. Owing to the exclusion of participants with a diagnosis of FTLD, the prevalence of language and executive impairment reported in this study relates only to mild impairments in non-demented patients with ALS, and the study is unable to comment on the incidence rates or nature of executive and language impairment of increasing degrees of severity in the wider ALS population.
Interpretations drawn from this study may be limited by the use of cognitive composite scores calculated from several heterogeneous assessment measures. While this avoids type I errors associated with multiple between-group comparisons and allows a focus on overall rates of impairment in executive and language domains, inspection of patient performance on individual measures (presented for the interested reader in table 3) would provide additional insights into the profiles of cognitive impairment seen in non-demented patients with ALS. In addition, the attempt to assess several areas of language functioning means that the language composite score included a greater number of language tests (relative to executive tests included in the executive composite), potentially rendering the study more sensitive to language than executive impairments.
In addition to the language and executive tests, a number of other tests were conducted as part of a comprehensive neuropsychological examination. A comparable memory domain score did not differentiate the ALS and healthy control groups, and the proportion of ALS and healthy control participants who showed impaired performance on the memory composite score did not significantly differ (see online supplementary material). Data were not considered further. The memory composite score included indices from a small number of memory assessments (relative to the language and executive composites), and a greater number of memory tests may have increased the study's sensitivity to detect memory impairments.
These limitations notwithstanding, our identification of language impairment that cannot be explained by executive dysfunction in a proportion of patients with ALS raises questions about the future assessment and ascertainment of mild cognitive change in ALS. Our findings also highlight the need to consider revising the current consensus criteria3 for the identification of cognitive impairment in ALS.
The study was supported by the Medical Research Council, the Motor Neurone Disease Association, UK and the Institute of Social Psychiatry. This work was also supported by the European Community's Health Seventh Framework Programme (FP7/2007–2013) (259867 to AA-C and CES). We would also like to acknowledge Dr J Ealing, Dr C Allen and Dr T Williams and the Dementias & Neurodegenerative Diseases Research Network (DeNDRoN) for facilitating recruitment at each centre. RGB, AA-C, CES and LHG receive salary support from the National Institute for Health Research (NIHR) Dementia Biomedical Research Unit at South London and Maudsley NHS Foundation Trust and King's College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Files in this Data Supplement:
- Data supplement 1 - Online supplement
Contributors LJT contributed to the design of the study, the collection of data, analysed the data, and wrote the manuscript. RGB supervised the study and revised the manuscript. ST contributed to the process of recruitment and data collection. AA-C, CES, PNL and CME revised the manuscript from a clinical perspective. LHG supervised the study, was responsible for the conception of the project, and revised the manuscript.
Funding The study was supported by the Medical Research Council, the Motor Neurone Disease Association, UK and the Institute of Social Psychiatry. This work was also supported by the European Community's Health Seventh Framework Programme (FP7/2007-2013) (259867 to AA-C and CES). RGB receives research support from Parkinsons UK, the Department of Health via the National Institute for Health Research (UK), Medical Research Council (UK), Alzheimer Society (UK), Alzheimer Research Trust (UK), and the Edmund J Safra Foundation (Switzerland). AA-C receives research support from the Motor Neurone Disease Association UK, the ALS Association and the ALS Therapy Alliance. CES receives research support from the Motor Neurone Disease Association UK, the Medical Research Council, the Wellcome Trust and Psychiatry Research Trust. PNL has received research support from the Motor Neurone Disease Association and the Wellcome Trust UK. LHG receives research support from Department of Health/National Institute for Health Research (NIHR) UK and the Motor Neurone Disease Association UK. She has also received support from Epilepsy Research UK, the Institute of Social Psychiatry and the Wellcome Trust UK.
Competing interests AA-C receives royalties from the publication of The Brain (Oneworld Publications) and The Genetics of Complex Human Diseases (Cold Spring Harbor Laboratory Press for a book). RGB has received travel expenses and honoraria for speaking and educational activities not funded by industry, and for activities funded by the following companies: UCB Pharma, GSK, Abbott Healthcare Products. CES has received travel expenses and honoraria acting as a consultant to GlaxoSmithKline. PNL has received honoraria or consultancy fees and travel expenses from Sanofi Aventis, GlaxoSmithKline (GSK), Acceleron, Cytokinetics, Neuyronova, and is or has been a member of advisory boards for GSK, Acceleron, Cytokinetics, Neuronova. LHG serves on the Scientific Awards Panel for Epilepsy Action (UK), has received travel expenses and honoraria for speaking and educational activities not funded by industry, receives royalties from the publication of Clinical Neuropsychology (Wiley, 2004, 2012) and The Clinical Psychologist's Handbook of Epilepsy (Routledge, 1997).
Ethics approval King’ College Hospital Research Ethics Committee.
Provenance and peer review Not commissioned; externally peer reviewed.